Despite the challenges currently seen in the cannabis marketplace and capital markets, Canada is touting the positives of its legalization process on the global stage.

During a meeting of the UN Commission on Narcotic Drugs on Monday (March 9), Michelle Boudreau, director general for Health Canada’s controlled substances department, provided an update on the status of the unregulated market compared to the legal space.

A report from Marijuana Moment indicates that the commentary from Boudreau came after the UN International Narcotics Control Board showed concern about cannabis legalization efforts.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

More and more countries around the world are now looking at the possibility of legalizing cannabis in some form or another.

According to Boudreau, the unregulated marijuana market has shrunk by nearly 30 percent since legalization came into effect in Canada. By the estimation of the Canadian government, the unregulated market has lost about C$2 billion worth of sales in that time.

Canada legalized cannabis for adult use in 2018 following a campaign promise from Prime Minister Justin Trudeau. A year later, the country introduced legal edible products into the mix.

However, health organizations are starting to wonder whether current cannabis regulations make sense. Boudreau said Canada will continue to track progress in the marketplace and impacts on health.

Following the legalization of cannabis, the country has seen a rush of interest in legal products followed by repeated demand-related issues in the supply chain.

In addition to supply challenges, the capital markets have faced a depression that is indicative of the state of the cannabis market in Canada.

Over a one year period, the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), an index containing a basket of leading cannabis names, has dropped in value by over 70 percent.

“We will continue to collect data and evaluate the impact of Canada’s new regulatory framework and will ensure that any future decisions are well informed by this data,” Boudreau said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less